cl 387785 has been researched along with Polycystic Kidney Diseases in 4 studies
CL 387785: structure in first source
N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}but-2-ynamide : A member of the class of quinazolines that is 4,6-diaminoquinazoine in which the one of the hydrogens attached to the amino group at position 4 has been replaced by a m-bromophenyl group while one of the hydrogens attached to the amino group at position 6 has been replaced by a but-2-ynoyl group.
Polycystic Kidney Diseases: Hereditary diseases that are characterized by the progressive expansion of a large number of tightly packed CYSTS within the KIDNEYS. They include diseases with autosomal dominant and autosomal recessive inheritance.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor." | 1.31 | Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor. ( Avner, ED; Chen, Y; Frost, P; Nakanishi, K; Sweeney, WE, 2000) |
| "Recessively transmitted polycystic kidney disease (PKD) in many murine models is characterized by the initial formation of proximal tubular cysts (stage 1), followed by growth and enlargement of renal collecting tubule (CT) cysts (stage 2)." | 1.30 | In vitro modulation of cyst formation by a novel tyrosine kinase inhibitor. ( Avner, ED; Frost, P; Futey, L; Sweeney, WE, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Torres, VE | 1 |
| Sweeney, WE | 3 |
| Wang, X | 1 |
| Qian, Q | 1 |
| Harris, PC | 1 |
| Frost, P | 3 |
| Avner, ED | 3 |
| Futey, L | 1 |
| Chen, Y | 1 |
| Nakanishi, K | 1 |
| Marfella-Scivittaro, C | 1 |
| Quiñones, A | 1 |
| Orellana, SA | 1 |
4 other studies available for cl 387785 and Polycystic Kidney Diseases
| Article | Year |
|---|---|
EGF receptor tyrosine kinase inhibition attenuates the development of PKD in Han:SPRD rats.
Topics: Animals; Disease Models, Animal; ErbB Receptors; Gastric Lavage; Injections, Intraperitoneal; Male; | 2003 |
In vitro modulation of cyst formation by a novel tyrosine kinase inhibitor.
Topics: Animals; Cell Division; Cell Survival; Disease Models, Animal; Enzyme Inhibitors; Epidermal Growth F | 1999 |
Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Mice; | 2000 |
cAMP-dependent protein kinase and proliferation differ in normal and polycystic kidney epithelia.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Animals; Cell Division; Cells, Cultured; Cyclic AMP; Cyclic | 2002 |